Ads
related to: iga nephropathy treatment current- Sign-up for Updates
Sign Up Today
to Receive Updates.
- Resource Downloads
Explore Downloadable Resources
With Useful Information.
- Dosing Information
See Our Recommended
Dosing & Treatment Schedule.
- Official HCP Website
Visit Our Official HCP Website for
More Information and Get Support.
- Sign-up for Updates
Search results
Results from the WOW.Com Content Network
IgA nephropathy (IgAN), also known as Berger's disease (/ b ɛər ˈ ʒ eɪ /) (and variations), or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney.
Sparsentan was approved in the US under accelerated approval based on reduction of proteinuria. [1] [5] [12] In September 2024, the US FDA converted the conditional approval in the kidney disease IgA nephropathy (IgAN) into a full approval based on positive long-term confirmatory results from the PROTECT Study demonstrating that sparsentan significantly slowed kidney function decline over two ...
Fostamatinib as a treatment for IgA nephropathy (IgAN) is in Phase II trials, which will conclude at the end of 2016. IgAN is a chronic autoimmune disease associated with inflammation in the kidneys that reduces their ability to successfully filter blood. There are currently no disease-targeted therapies for IgAN.
English: What is IgA nephropathy? IgA nephropathy, sometimes called Berger disease, is a type of nephritic syndrome where abnormal IgA antibody is formed, which results in immune complex deposition in the glomerular mesangium, leading to kidney disease. This video covers the pathophysiology, signs and symptoms, and treatment of IgA nephropathy.
Liprotamase (Sollpura), Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy [1] [2] is currently in Phase 2 clinical trial.
Povetacicept is in phase 3 testing as a treatment for IgA nephropathy, a chronic kidney disease. VX-880 is Vertex's most advanced candidate that holds the potential to cure type 1 diabetes.
IgA nephropathy: Kidneys: IgA autoantibodies Confirmed 3.5 per 100,000 [47] Membranous nephropathy: Kidneys: Anti-PLA2R antibodies Confirmed 10 per 100,000 [48] Lupus nephritis: Kidneys: Anti-dsDNA, Anti-Sm, Anti-nuclear antibodies Confirmed Up to 60% of those with Lupus [49] Interstitial nephritis: Kidneys: Various autoantibodies Probable
IgA nephropathy, also known as Berger's disease, is the most common type of glomerulonephritis, and generally presents with isolated visible or occult hematuria, occasionally combined with low grade proteinuria, and rarely causes a nephritic syndrome characterised by proteinuria, and visible blood in the urine. IgA nephropathy is classically ...
Ads
related to: iga nephropathy treatment current